CADD/AIDD

Search documents
泓博医药2025上半年营收3.53亿元 CADD/AIDD技术平台已累计为95个新药项目提供技术支持
Quan Jing Wang· 2025-08-28 02:04
Core Insights - The company reported a revenue of 353 million yuan for the first half of 2025, representing a year-on-year growth of 32.73% [1] - The net profit attributable to shareholders reached 24.76 million yuan, with a year-on-year increase of 54.99% [1] - The company's R&D investment amounted to 18.99 million yuan, accounting for 5.39% of its revenue [1] Financial Performance - Revenue for H1 2025: 353 million yuan, up 32.73% year-on-year [1] - Net profit attributable to shareholders: 24.76 million yuan, up 54.99% year-on-year [1] - Deducted net profit: 20.16 million yuan, up 115.02% year-on-year [1] Industry Context - The global biopharmaceutical industry is experiencing a recovery in financing conditions and an increase in domestic innovative drug licensing activities [1] - The company is leveraging its competitive advantages to enhance collaboration with existing clients and expand its market presence through various marketing activities [1] R&D and Technical Platforms - The company has invested 18.99 million yuan in R&D, with 742 R&D personnel making up 68.39% of the total workforce [1] - The CADD/AIDD technology platform has supported 95 new drug projects, with 7 entering clinical trials [2] - The enzyme chemistry technology platform has developed a comprehensive library of industrial enzymes and customized green synthesis routes for multiple products [2] Service Offering - The company provides one-stop comprehensive services for new drug R&D and commercial production, focusing on drug discovery and process development [2] - It aims to build a comprehensive technical service platform covering drug discovery and process research, along with a commercial production platform for key intermediates and proprietary products [2]